In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
This commentary from IPC Board Member Lluís Puig examines inference-based guidance for managing immune checkpoint inhibitor-induced psoriasis and discusses how biologics and targeted systemic therapies can be used safely alongside cancer immunotherapy.
Jason Hawkes provides expert commentary on an international multicenter study evaluating two-year drug survival, efficacy, and safety of acitretin, cyclosporine, and methotrexate in pediatric psoriasis patients.
Artificial intelligence is transforming psoriasis care by improving diagnosis accuracy, guiding treatment decisions, and supporting personalized management.
IPC Councilor Dr. Matias Maskin provides expert commentary on a recent study linking TNF-alpha inhibitors to lower psoriatic arthritis risk in severe psoriasis. This ten-year study compares biologics with phototherapy.
IPC Councilor Dr. Tiago Torres provides expert commentary on research linking psoriasis severity to cardiovascular disease via systemic inflammation. The study identifies GlycA as a key biomarker partially mediating this connection using robust mediation models and data from US and Swedish cohorts. Learn how these findings support a systemic view of psoriasis and its implications for cardiovascular risk management.
National cohort data from Taiwan reveal a strong link between immune checkpoint inhibitor (ICI) therapy and new-onset psoriasis in cancer patients, especially in older men. Dermatologists should understand this emerging risk to improve the detection and management of ICI-related skin reactions.
Discover the link between obesity and psoriasis, the impact of inflammation on disease progression, and the emerging role of GLP-1 receptor agonists as a promising therapeutic strategy for weight loss and psoriatic management.
Investigate how maintaining good cardiovascular health, measured by Life’s Essential 8 (LE8), may reduce the risk of developing psoriatic disease, regardless of genetic susceptibility. This UK Biobank study highlights the importance of lifestyle factors in preventing psoriatic disease.
This article explores the clinical practice of dose de-escalation in psoriasis treatment, focusing on the GUIDE study’s findings on patients achieving long-term disease control with extended dosing intervals of guselkumab. It highlights key factors like early intervention, biomarker reductions, and the potential for disease modification, offering insights into optimizing psoriasis management strategies.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
